The FDA unveiled draft guidance aimed at enabling “plug and play” approvals for personalized gene therapies that target different mutations within the same gene. The proposal would let companies pursue initial approval for one mutation using a more traditional clinical pathway, then support subsequent mutation-specific clearances with laboratory data rather than full new clinical trials. Regulators focused on scenarios where each individual mutation is so rare that stand-alone clinical trials are impractical. In the draft, FDA describes how future approvals could be bounded through an “individualized feature space” defined in the original application. The agency positioned the approach as part of broader efforts to improve access for rare-disease patients. The plan was immediately tied by analysts to pipeline developers in the base-editing and gene-editing space. Prime Medicine was specifically referenced in connection with the potential applicability of the framework, and Beam Therapeutics CEO John Evans argued the approach aligns with the science behind base editing. The FDA is also convening discussions related to its broader “Rare Disease Framework Initiative,” signaling continued movement toward standards based on individual conditions rather than a single uniform model across rare indications.